StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
CTNMContineum Therapeutics, Inc.
stockpulse.co.kr
Nasdaq
$8.19▼ 1.21%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $306.2MShares out 37.4M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

12
  • 2d agoAfter-hours26.10.23 05:15
    SCHEDULE 13GOwnership#●●●

    Contineum Therapeutics, Inc.

    Trails Edge Capital Partners, LP and Trails Edge Biotechnology Master Fund, LP have filed a joint Schedule 13G regarding their ownership of Class A common stock in Contineum Therapeutics, Inc. This filing formalizes the agreement between these entities to jointly manage and report their holdings.…more

    $8.19-1.21%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 10.1After-hours26.10.02 05:21
    144Ownership

    Contineum Therapeutics, Inc.

    Insider Lorrain Daniel S. of Contineum Therapeutics, Inc. has filed a Form 144 to propose the sale of company securities. This is a standard notification regarding an insider's plan to dispose of their holdings.…more

    $8.19-1.21%vs prev close
    View filingShare
  • 9.14After-hours26.09.15 05:07
    8-KKey event

    Contineum Therapeutics, Inc.

    Contineum Therapeutics announced that the Phase 2 MOONLIGHT-1 clinical trial of JNJ-5120/PIPE-307 for major depressive disorder failed to meet its primary efficacy endpoint. The drug is being developed under a global license agreement with Johnson & Johnson, and further analysis of exploratory data is currently underway.…more

    $8.19-1.21%vs prev close
    View filingShare

11 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 9.15Regular26.09.16 00:07
    Bullish#●●●#●●●#●●●

    Contineum Therapeutics Shares Slide Following Phase 2 Depression Drug Trial Failure…more

    Contineum Therapeutics shares fell after its depression drug candidate, developed with Johnson & Johnson, failed to meet primary endpoints in a Phase 2 trial. The company is currently evaluating the trial data to determine the next steps for the program.…more

    $8.19-1.21%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    ShareBenzinga
  • 9.14After-hours26.09.15 05:09

    ●●●●●●●● ●●●●● ●●●●●●

    Contineum Therapeutics announced that its Phase 2 MOONLIGHT-1 trial for the depression drug JNJ-5120 failed to meet its primary efficacy endpoint. The company is currently analyzing exploratory data and consulting with Johnson & Johnson to determine the next steps for the program.…more

    $8.19-1.21%vs prev close
    ShareBenzinga

1 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →